The company clarified that none of the observations were related to data integrity. Zydus added that it will work closely with the USFDA to address and resolve the observations expeditiously.
In a separate filing, the company also informed that the USFDA conducted a Pre-Approval Inspection (PAI) at its formulation manufacturing facility located in SEZ – II, Ahmedabad. The inspection, which covered three products and general current Good Manufacturing Practices (cGMP), was conducted from 11 August to 13 August 2025. This inspection concluded with no observations, indicating a clean outcome.
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company’s consolidated net profit shed 1% to Rs 1,170.90 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24.
The counter added 1.35% to end at Rs 1,002.40 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."